In this week’s news, Andelyn Biosciences predicts trends in cell and gene therapy, the key learnings from 2022 in pharma and more.
Andelyn Biosciences predicts trends in cell and gene therapy in 2023. Laura A. Kerepesi, PhD, associate director – Preclinical Manufacturing, Andelyn Biosciences shares insight on the key learnings from 2022 within the C> sector, as well as upcoming 2023 trends around gene therapy.
Pfizer CentreOne’s Tom Wilson builds on that analogy as it relates to pharma’s manufacturing and business models and the effects of disruptions in the supply of active pharmaceutical ingredients (APIs). The industry’s goal is straightforward: get medicine to patients. If the supply chain is broken, critical medicine’s API supply is disrupted, and that essential promise can be broken.
EPM asked several pharma industry experts what key learnings and takeaways they are taking from 2022 within pharma manufacturing.
“As we emerge from the pandemic, there have been signs of an investment slowdown after record VC funding levels driven by Covid treatment and prevention, although investment by VC remains at historically high levels.” Christian Dowdeswell, vice president, head of Commercial Development, Small Molecules, Lonza.
Protein seen in dry eye disease injuries could have therapeutic potential. Researchers tracked the development of stem cells to epithelial cells in the cornea of mice to understand how different disease processes affected gene expression.
While the pandemic brought new entrants into the market, vaccine manufacturing remains a complex activity undertaken by a limited number of companies with the overall picture largely unchanged by Covid-19.
10 Clinical Trials to watch in the first half of 2023. Highly anticipated study results are expected in Alzheimer’s, obesity, and Huntington’s disease, while a pair of high-priced acquisitions could be put to the test.
Ablaze Pharmaceuticals has initiated a development and manufacturing services agreement with Yonghe Pharmaceutical Technology to develop a series of targeted radiopharmaceutical therapy (TRT) products.
Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), and The Vistria Group announced that they have completed the acquisition of Alcami Corporation, a leading pharmaceutical contract development and manufacturing organization (CDMO), from funds affiliated with Madison Dearborn Partners and Ampersand Capital Partners.
27th June, 2022
Competition is more aggressive than ever in our space and a key to differentiation...Read more
18th January, 2021
Over the past six months, our Founder and Global President Raman Sehgal has conducted...Read more